Stockreport

Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD

Verona Pharma plc - American Depositary Shares  (VRNA) 
US:NASDAQ Investor Relations: nasdaq.com/symbol/vrna/real-time
PDF LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, a [Read more]